Mitsubishi LSI announces clinical trial for treatment of cerebral infarction with MUSE cells

The Mitsubishi Life Science Institute has launched a clinical trial with MUSE cells (multi-lineage differentiating stress enduring cells) for the treatment of acute myocardial infarction in January, 2018. Now, LSI annunces a clinical trial CL2020 with MUSE cells targeting patients with cerebral infarction. In this trial, MUSE cells will be administered intravenously.

LSI news release, September 3, 2018

Most popular posts:

This website stores cookies on your computer. These cookies are used to provide a more personalized experience and to track your whereabouts around our website in compliance with the European General Data Protection Regulation. If you decide to to opt-out of any future tracking, a cookie will be setup in your browser to remember this choice for one year.

Accept or Deny